Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

Castle Biosciences Inc (CSTL)

  • Company Report
  • Aug. 08, 2022, 13:07 UTC
  • 37

Castle Biosciences - Second Quarter 2022

Comment Full text

Reata Pharmaceuticals Inc. (RETA)

  • Company Report
  • Aug. 08, 2022, 03:48 UTC
  • 40

Reata Pharmaceuticals Inc. - Second Quarter 2022

Comment Full text

Pacific Biosciences of California Inc (PACB)

  • Company Report
  • Aug. 08, 2022, 03:16 UTC
  • 39

New Form 10-Q for Pacific Biosciences of California Inc

Comment Full text

Incyte Corporation (INCY)

  • Company Report
  • Aug. 05, 2022, 14:41 UTC
  • 39

Weekly Summary Alert for Incyte Corporation

Comment Full text

Codexis Inc. (CDXS)

  • Company Report
  • Aug. 05, 2022, 13:41 UTC
  • 41

New SEC Form for Codexis, Inc.

Comment Full text

BioCryst Pharmaceuticals Inc (BCRX)

  • Company Report
  • Aug. 05, 2022, 13:26 UTC
  • 35

New Form 10-Q for BioCryst Pharmaceutical, Inc.

Comment Full text

Vertex Pharmaceuticals (VRTX)

  • Company Report
  • Aug. 05, 2022, 13:14 UTC
  • 39

New Form 10-Q for Vertex Pharmaceuticals

Comment Full text

Myriad Genetics Inc. (MYGN)

  • Company Report
  • Aug. 05, 2022, 13:11 UTC
  • 39

New Form 10-Q for Myriad Genetics, Inc.

Comment Full text

EyePoint Pharmaceuticals (EYPT)

  • Company Report
  • Aug. 05, 2022, 11:19 UTC
  • 37

New Form 10-Q for EyePoint Pharmaceuticals, Inc.

Comment Full text

Relmada Therapeutics Inc. (RLMD)

  • Company Report
  • Aug. 05, 2022, 07:08 UTC
  • 37

Relmada Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022

Comment Full text
  • Previous
  • 65
  • 66
  • 67
  • 68
  • 69
  • Next

Search

News categories

  • Technical Exchange News(9805)
  • Event(407)
  • SEC News(162972)
  • FDA Approval(9285)
  • Company Report(721)
  • Business News(110339)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin